Clinical Trials
3
Active:0
Completed:2
Trial Phases
1 Phases
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 3
1 (100.0%)A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS
Phase 3
Recruiting
- Conditions
- Prader-Willi Syndrome
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-09-05
- Lead Sponsor
- Foundation for Prader-Willi Research
- Target Recruit Count
- 102
- Registration Number
- NCT06144645
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
Natural History Study of Serious Medical Events in PWS
Completed
- Conditions
- Prader-Willi Syndrome
- First Posted Date
- 2018-10-24
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Foundation for Prader-Willi Research
- Target Recruit Count
- 700
- Registration Number
- NCT03718416
- Locations
- 🇺🇸
Foundation for Prader-Willi Research (FPWR), Walnut, California, United States
Weight Change in PWS Over Six Months
Completed
- Conditions
- Weight Change, Body
- First Posted Date
- 2018-07-12
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Foundation for Prader-Willi Research
- Target Recruit Count
- 180
- Registration Number
- NCT03585244
- Locations
- 🇺🇸
Remote, Walnut, California, United States
News
FDA Approves First Treatment for Hyperphagia in Prader-Willi Syndrome
The FDA has approved VYKAT XR (diazoxide choline) as the first therapy specifically targeting hyperphagia in Prader-Willi syndrome, offering new hope to patients and families affected by this rare genetic disorder.